P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma

María-Victoria Mateos; Ajai Chari; Saad Usmani; Hartmut Goldschmidt; Katja Weisel; Keqin Qi; Anil Londhe; Sandhya Nair; Xiwu Lin; Lixia Pei; Eric Ammann; Rachel Kobos; Jennifer Smit; Trilok Parekh; Alexander Marshall; Mary Slavcev; Philippe Moreau

doi:10.1016/S2152-2650(22)00611-5

$P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma$

Abstract

Peer reviewed

P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma

María-Victoria Mateos, Ajai Chari, Saad Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, …

Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S192-S193

08/2022

DOI: 10.1016/S2152-2650(22)00611-5

View Online

Details

Title: Subtitle: P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
Creators: María-Victoria Mateos
Ajai Chari
Saad Usmani
Hartmut Goldschmidt
Katja Weisel
Keqin Qi
Anil Londhe
Sandhya Nair
Xiwu Lin
Lixia Pei
Eric Ammann
Rachel Kobos
Jennifer Smit
Trilok Parekh
Alexander Marshall
Mary Slavcev
Philippe Moreau
Resource Type: Abstract
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S192-S193
DOI: 10.1016/S2152-2650(22)00611-5
ISSN: 2152-2650
eISSN: 2152-2669
Language: English
Date published: 08/2022
Academic Unit: Epidemiology
Record Identifier: 9984364388202771

Metrics

35 Record Views